The enterohepatic circulation (EHC) of drugs is often the result of the direct glucuronidation, excretion of the metabolite into bile, followed by hydrolysis to the aglycone by the gut microbiome and finally reabsorption of drug into the systemic circulation.
| INTRODUC TI ON
Enterohepatic circulation EHC) is a process composed of a circuit of hepatic metabolism, biliary excretion, gut microbiome metabolism, followed by reabsorption from the gut back to systemic circulation.
1,2 Forty-five drugs were identified that undergo EHC in a recent review article. 3 Among these, the drug itself may be directly secreted into bile without undergoing metabolism; others undergo conjugation in the liver, such as glucuronidation and sulfation, then the metabolites are excreted in bile, stored in gallbladder, and released to the gut, where they undergo hydrolysis back to the parent drug by gut microbiome. 2 Pharmacokinetic parameters such as half-life (t 1/2 ), volume of distribution (V dss ), area under the concentration-time curve AUC) and bioavailability often are substantially affected by EHC with orally administered drugs, 2 demonstrating the importance of assessing the magnitude of EHC to model the pharmacokinetic/pharmacodynamics PK/PD) for a clinical candidate in drug discovery. This is especially true for compounds where a minimum concentration needs to maintained over a 24 hours period. A recent study investigated the fraction of hepatic metabolism fm) in dogs and suggested EHC will also affect the cumulative fm estimation of drugs that are metabolized by both P450s and UGTs in the liver, when the glucuronide metabolites are excreted into bile and hydrolyzed by gut microbiome during the process of EHC. 4 In the present study, the EHC of canagliflozin, known to be cleared by P450 mediated oxidation and UGT mediated O-glucuronidation in human, 5, 6 and DPTQ 2-2,6-dichlorophenyl)-1-1S,3R)-5-2-hydroxy-2-methylpropyl)-3-hydroxymethyl)-1-methyl-3,4 dihydroisoquinolin-21H)-yl)ethan-1-one, 7 a discovery project compound primarily cleared by hepatic metabolism of UGT and P450, were investigated in dog. The dog was used since it is a preclinical species that is more physiologically relevant to human than rodents with respect to bile secretion, 8 biliary drug excretion 9 and colonic absorption. 10 The PK profiles were compared between bile duct cannulated (BDC) and intact dogs after a single intravenous administration of the drugs, and the distribution of O-glucuronide metabolites in plasma, bile, urine and feces was quantified to explore the fate of the metabolites during EHC. Subsequent in vitro hepatic metabolism and permeability studies were performed to characterize the physicochemical and metabolic properties that favor EHC. Given the disposition of canagliflozin has been reported for humans, 11 a comparison of the in vitro and in vivo metabolic and excretion data of canagliflozin in human to those obtained with dog was performed in order to identify the species differences in the process of EHC.
| MATERIAL S AND ME THODS

| Chemicals and reagents
Canagliflozin, 
| Animals
Male beagle dogs were obtained from Charles River Laboratories Inc (Wilmington, MA). Pharmacokinetic (PK) studies in intact dogs were conducted at Covance (Greenfield, IN), while bile duct cannulation surgery and PK studies were conducted in these dogs at Covance (Madison, WI). Dogs (weight: 9-12 kg), were acclimated prior to study initiation according to Standard Operating Procedures (Covance). All intravenous compound administration was by an intravenous catheter implanted in the cephalic vein. Access to food and water was allowed ad libitum. All animal procedures were approved by the Institutional Animal Care and Use Committee at Covance.
Replacement bile was not administered during the study since collection of bile was scheduled for a period of 48 hours, replacement is typically administered for studies lasting more than 60 hours.
| In vivo pharmacokinetics and excretion studies
Canagliflozin and DPTQ, both at 0.5 mg/kg, were administered in- 
| Determination of pharmacokinetic parameters
Noncompartmental pharmacokinetic parameters were calculated using Watson version 7.4 (Thermo Scientific, Waltham, MA).
Statistical significance of differences for pharmacokinetic parameters between two groups was examined with Student's t test using Sigmaplot 12.5 (Systat Software Inc, San Jose, CA).
| Determination of fraction of CYP-mediated oxidative metabolism in hepatocytes
The intrinsic clearance was determined in cryopreserved dog and human hepatocytes essentially as described previously. 4 The assay 
| Hepatocyte metabolite profile
Cryopreserved dog and human hepatocytes were obtained from 
| Bi-directional transport across MDCK cells
MDCKII cells stably expressing human wild-type P-gp were obtained from the Netherlands Cancer Institute Amsterdam, The Netherlands). MDCK cells were maintained and the assay was conducted essentially as described previously. 
without treatment of β-glucuronidase from the one with enzyme treatment.
| Liver and kidney microsomal glucuronidation assay
Intrinsic clearance of the compounds by glucuronidation was con- The microsomal unbound fraction both with and without 2% BSA was determined as described previously. 15 
| LC-MS/MS quantification of drugs and metabolites
Canagliflozin and DPTQ in plasma, bile, urine and feces were quantified using LC-MS/MS. All samples plasma, urine and bile) were mixed with an organic internal standard solution essentially described previously, 15 to precipitate protein and centrifuged, and the resulting supernatants were analyzed using AB Sciex API 4000 quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) equipped with a TurboIonSpray interface. The feces samples were homogenized in MeOH:H 2 O (1:1) and shaken vigorously to obtain slurry.
The homogenates then went through the sample extraction along with other matrices. The blank plasma, urine, bile and feces was spiked with internal standard for calibration curve. 
| RE SULTS
| Pharmacokinetics of drugs in intact and bile duct cannulated (BDC) dog
Physicochemical properties molecular weight (MW), clogP and pKa (Table 1 ) of canagliflozin and DPTQ were calculated using tools supplied by ChemAxon (http://www.chema xon.com).
Topological polar surface areas TPSA) were calculated based on the method described previously. 16 The number of hydrogen bond accompanied by the flat and tailing elimination phase and increased volume of distribution at steady state (V dss ) ( Figure 2 and Table 2 ), suggesting the enterohepatic circulation (EHC).
| Recovery of parent drugs and glucuronides in urine, feces and bile of intact and BDC dogs
The extent of renal excretion of canagliflozin, DPTQ and canagliflozin-glucuronides was negligible (<1% of dose) and the renal recovery of DPTQ-glucuronide was low (<5% of dose). The biliary excretion of parent drugs represented 4.66 and 8.91% of dose for canagliflozin and DPTQ respectively, indicating the metabolism was primarily responsible for clearance of both drugs in dog (Table 3 ). The biliary excretion of glucuronide metabolites represented 15% of dose for canagliflozin and 35.8% of dose for DPTQ in BDC dog, whereas the fecal recovery of glucuronide metabolites was 0.37% for canagliflozin and 0.80%
for DPTQ in intact dog during 48 hours, suggesting the hydrolysis of the glucuronides after biliary excretion in the gut. The significantly increased fecal recovery of the parent drug of DPTQ in intact as compared to BDC dog was also consistent with the hydrolysis of DPTQ-Oglucuronides by gut microbiome and excretion to feces (Table 3 ).
| In vitro hepatocyte Cl int and metabolite profile
The intrinsic clearances (Cl int ) of canagliflozin and DPTQ characterized by parent loss in dog hepatocytes were inhibited 12.7 and 46.5%
by ABT, respectively ( Table 4 ).
The subsequent dog hepatocyte metabolite profile indicated that oxidation and glucuronidation were major metabolic pathways for DPTQ in dog hepatocytes ( Figure 3 and Table 5 ). In the presence of ABT, the primary oxidative metabolite C was not detected, whereas glucuronide metabolite metabolite B) peak in the profile was not meaningfully reduced <20% change for metabolite/internal standard peak area ratio). Product A P+O+glucuronidation) was a secondary metabolite and the formation was inhibited by ABT.
The metabolite profile for DPTQ in human hepatocytes was similar to that observed with dog. For canagliflozin, the metabolites B and D were the two direct glucuronidation products in dog hepatocytes, reported as M5 and M7 reported previously. 5 The secondary metabolite A (P+O+sulfation) is likely formed by oxidation followed by sulfation according to the inhibition of the product Note: Dogs were given canagliflozin and DPTQ at 0.5 mg/kg by IV bolus. Values were derived from plots shown in Figure 2 . Results shown represent mean ± SD from four animals. a P < 0.01 compared to the parameters in intact animals. 
| Liver and kidney microsomal glucuronidation
The unbound intrinsic clearances (Cl int,u ) determined by parent loss in liver and kidney microsomes were examined in order to understand whether the O-glucuronides detected in urine are produced by glucuronidation in the kidney or are formed in the liver, excreted into blood, and then eliminated from circulation by the kidney. The microsomal incubation was conducted with or without 2% bovine serum albumin (BSA), which is known to reduce K m values for substrates of UGT isoforms that are inhibited by long-chain unsaturated fatty acids released by incubation with human liver microsomes. 18 The Cl int,u was higher in the presence of BSA in human microsomes for canagliflozin (liver and kidney) and DPTQ (liver), as well as in dog liver microsomes for DPTQ ( Table 6 ). The substantial
Cl int,u of glucuronidation in human kidney suggested the canagliflozin O-glucuronides detected in human urine could be locally produced in the kidney (Table 6 ). The negligible glucuronidation in both liver and kidney microsomes of dog was consistent with negligible circulating and urinary recovery of canagliflozin-O-glucuronides. In contrast, the glucuronidation activity towards DPTQ was abundant in dog liver microsomes but not detected in kidney microsomes, suggested the urinary recovery of DPTQ-O-glucuronide in dog is mainly from circulation after hepatic metabolism. The lower glucuronidation activity in human liver microsomes was consistent with lower hepatocyte Cl int compared to dog for DPTQ, and glucuronidation intrinsic clearance by human kidney microsomes was not detected (Table 6 ).
| MDCK permeability and gut reabsorption
Passive membrane permeability was high for DPTQ and moderate for canagliflozin (Table 7) . DPTQ was not a P-gp substrate, whereas canagliflozin was determined to be a P-gp substrate in a P-gp-transfected TA B L E 3 Recovery of parent and glucuronide metabolite for canagliflozin and DPTQ in bile, urine and feces in bile-duct cannulated (BDC) and intact dog Note: Dogs were given canagliflozin and DPTQ at 0.5 mg/kg by IV bolus. The bile, urine and feces samples were collected in BDC dogs, and the urine and feces was collected in intact dog over 48 hours post-dose. The bile, urine and feces samples after canagliflozin and DPTQ administration were separated into two aliquots, one for bioanalytical assay of parent drugs (1), and one treated with β-glucuronidase (2) and analyzed for parent drugs as described in Materials and Methods. The concentration of O-glucuronides was determined by subtracting the concentration of (1) from (2). Results shown represent means ± SD (n = 4). Abbreviations: NA, bile concentration in intact dog was not available; ND, the concentration was below the quantitative limit 1 ng/mL. a P < 0.05 compared to that in BDC dog. (Table 7) . Compounds with relatively high numbers of hydrogen bond donors and acceptors as well as higher polar surface area are often P-gp substrates, 12 as is the case with canagliflozin (Table 1) . This also agrees with a previous report that canagliflozin is a P-gp substrate. 6 The differences in the permeability and P-gp liability are likely to determine the extent of reabsorption to portal circulation and subsequent EHC. Note: Hepatocyte metabolite identification was conducted with and without pre-incubation of 1 mmol/L ABT as described in Materials and Methods. The peak area values were derived from plots in Figure 3 . Abbreviations: P, parent drug; IS, internal standard; RT, retention time; ND, not detected. Note: Incubation contained 2 µmol/L compound and 0.5 mg/mL liver and kidney microsomes with and without 2% BSA, as described in Materials and Methods. The unbound Cl int (in the parenthesis) was calculated using Cl int divided by microsomal unbound fraction. Results shown represent average of two independent experiment. Abbreviations: ND, Cl int < 1.8 µL/min/mg protein, the quantitative limit.
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TA B L E 6 Hepatic and kidney UGT Cl int and unbound Cl int of canagliflozin and DPTQ
| D ISCUSS I ON
Enterohepatic circulation (EHC) can increase apparent volume of distribution (V dss ) and prolong half-life (t 1/2 ) of drugs. The more extensive the recycling, the more prolonged the t 1/2 and the greater the volume increase. 19 In the BDC dog, the EHC is blocked and the increase in apparent V dss and prolonged t 1/2 are no longer observed (Figure 4 . Therefore, the differences in the PK profiles and the levels between dog and human from a translational perspective (Table 8 ).
The EHC of canagliflozin in human was also reported to be negligible. 11 However, the underlying mechanism resulting in the same outcome was distinct between dog and human. Glucuronidation represented the major hepatic metabolic pathways in human for canagliflozin, whereas oxidation is primarily responsible for the hepatic metabolism in dog as indicated in previous publications 5, 6 and the present study. Although the hepatic Cl int of canagliflozin was not substantially inhibited by ABT in dog, the formation of the carboxylic acid metabolite by dehydrogenase relative to glucuron- In contrast, the circulating AUC of DPTQ-glucuronides was 33% of AUC of DPTQ in dog, with the resulting 1.4%-3.7% urinary recovery of O-glucuronides of DPTQ due to efflux of glucuronide metabolites formed in the liver, given the kidney glucuronidation of DPTQ was negligible and much lower than that in the liver. Evidence shows that the EHC for DPTQ was not extensive since there was little impact on AUC and clearance between intact and BDC dogs. It is due to the low hepatic extraction of DPTQ, since the magnitude of EHC is associated with hepatic extraction ratio; a higher extraction ratio was shown to cause more extensive EHC, 21 whereas DPTQ displayed very low hepatic extraction.
Given the complexity in the EHC, the PK profile and parameters were less variable for canagliflozin in both animal groups and DPTQ in the BDC dog compared to DPTQ in intact dog. The dog is generally considered as the most biologically relevant preclinical species in investigating biliary excretion of xenobiotics. 8, 9 In addition, the dog model is considered a suitable surrogate for the estimation of human colonic absorption of passively absorbed drugs. 10 Gaps still exist, however, with respect to species differences in the hepatic ef- ; acyl-glucuronides could also undergo rearrangement and produce β-glucuronidase resistant species 28 that would complicate the assessment of EHC.
In conclusion, we demonstrated the hepatic UGT metabolism and/or permeability are crucial to EHC using canagliflozin and DPTQ as tool molecules. The models and the assays utilized in the present study, as summarized in Figure 4 and 
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